Daratumumab/Hyaluronidase-fihj

Total Revenue Increased 41% YOY to $326 million and Royalty Revenue Increased 65% YOY to $206 million Net Income Increased 77% YOY to $165 million; Adjusted EBITDA Increased 65% YOY to $226 million; GAAP Diluted EPS Increased 85% YOY to $1.33; Non-GAAP Diluted EPS Increased 69% YOY to $1.541 Raising 2025 Financial Guidance Ranges for Total Revenue to $1,275 - $1,355 million, Representing YOY Growth of 26% - 33%, Adjusted EBITDA to $865 - $915 million, Representing YOY Growth of 37% - 45% and Non-GAAP Diluted EPS to $6.00 - $6.40, Representing YOY Growth of 42% - 51%1 Announcing Third $250 million Share Repurchase Tranche Under $750 million Authorized Plan SAN DIEGO, Aug. 5, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the second quarter ended June 30, 2025, provided an update on its recent corporate activities and raised its 2025 financial guidance. "We are very excited to report another quarter of exceptional growth with a 65% increase in royalty revenue driven by our current three blockbuster therapies, DARZALEX SC, Phesgo, and VYVGART Hytrulo. In the second quarter, four notable approvals include RYBREVANT SC in Europe, VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in Europe and the VYVGART Hytrulo pre-filled syringe for gMG and CIDP in the U.S and Europe. Additional regulatory milestones were achieved with ENHANZE, including new indications and geographic expansion for DARZALEX SC, Opdivo SC, HYQVIA and Phesgo, which will further accelerate our future growth trajectory and enhance patient access. Based on the strong performance and growth trends, we are pleased to increase our full-year 2025 financial guidance ranges for the second time this year," said Dr. Helen Torley, President and CEO, Halozyme. "The strong results highlight the momentum and durability across our business, powered by high-margin royalty streams and increasing global demand for our industry-leading ENHANZE drug delivery technology. In the quarter, we completed a total of $303 million in share repurchases, including the $250 million program that we announced in May. Our outperformance and strong cash generation supports a balanced capital allocation strategy, including investing in growth through M&A and returning capital to shareholders," concluded Dr. Torley. Second Quarter and Recent Corporate Highlights: In June 2025, Halozyme initiated the third $250 million share repurchase tranche under the $750 million approved program from February 2024, of which $53.5 million was used to repurchase approximately 1.0 million shares at an average price of $52.40 per share in June 2025 for a total of $303.4 million of share repurchases in the second quarter. In May 2025, Halozyme announced a second $250 million share repurchase under the $750 million approved program from February 2024. The second $250 million share repurchase was completed in June 2025, resulting in a total purchase of 4.8 million shares at an average price of $52.09 per share. In April 2025, Halozyme filed a patent infringement lawsuit against Merck Sharp & Dohme Corp. ("Merck") in the U.S. District Court in New Jersey alleging that Merck is using Halozyme's patented MDASE™ subcutaneous ("SC") drug delivery technology to develop SC Keytruda. Halozyme is seeking damages and injunctive relief to stop Merck's infringement of Halozyme's MDASE™ intellectual property. Second Quarter and Recent Partner Highlights: In July 2025, Janssen announced the European Commission approved a new indication for DARZALEX® SC as a monotherapy for the treatment of adult patients with smouldering multiple myeloma ("SMM") at high risk of developing multiple myeloma. In June 2025, Takeda announced the Ministry of Health, Labour and Welfare in Japan approved HYQVIA® SC with ENHANZE® for treatment of patients with chronic inflammatory demyelinating polyneuropathy ("CIDP") and multifocal motor neuropathy. In June 2025, argenx announced European Commission approval of VYVGART® SC with ENHANZE® for the treatment of adult patients with progressive or relapsing active CIDP after prior treatment with corticosteroids or immunoglobulins. VYVGART® SC injection is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional. In May 2025, Bristol Myers Squibb received European Commission approval of Opdivo® SC, the SC formulation of Opdivo® (nivolumab) developed with ENHANZE® for use across multiple adult solid tumors, resulting in the recognition of $12.0 million in milestone revenue. In May 2025, argenx initiated a Phase 1 study to evaluate ARGX-213 with ENHANZE®. In May 2025, Janssen announced the U.S. Food and Drug Administration ("FDA") Oncologic Drug Advisory Committee voted in favor of the benefit-risk profile of DARZALEX Faspro® for the treatment of adult patients with high risk SMM. In April 2025, Roche received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending an update to the European Union ("EU") label for Phesgo® for human epidermal growth factor receptor 2-positive breast cancer. Administration of Phesgo® outside of a clinical setting (such as in a person's home) by a healthcare professional will be possible, once safely established in a clinical setting. In April 2025, argenx received FDA approval of VYVGART® Hytrulo prefilled syringe for self-injection for the treatment of adult patients with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive and adult patients with CIDP. In April 2025, Janssen received European Commission marketing authorization of the SC formulation of RYBREVANT® (amivantamab) with ENHANZE®, in combination with LAZCLUZE® (lazertinib), for the first-line treatment of adult patients with advanced non-small cell lung cancer ("NSCLC") with epidermal growth factor receptor ("EGFR") exon 19 deletions or exon 21 L858R substitution mutations. Additionally, RYBREVANT® (amivantamab) is approved as a monotherapy for adult patients with advanced NSCLC with activating EGFR exon 20 insertion mutations after the failure of platinum-based therapy. This represents the tenth partnered product with ENHANZE® to be commercialized. In May 2025, amivantamab was made available to patients in the EU resulting in a $10.0 million milestone payment. In April 2025, Janssen received European Commission approval for an indication extension of DARZALEX® SC in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma regardless of transplant eligibility. Second Quarter 2025 Financial Highlights: Revenue was $325.7 million, compared to $231.4 million in the second quarter of 2024. The 41% year-over-year increase was primarily driven by royalty revenue growth and an increase in milestone revenues. Revenue included $205.6 million in royalties, an increase of 65% compared to $124.9 million in the second quarter of 2024, primarily attributable to increases in revenue of DARZALEX® SC, VYVGART® Hytrulo and Phesgo®. Cost of sales was $46.4 million, compared to $39.6 million in the second quarter of 2024. The increase in cost of sales was primarily due to an increase in product sales and labor allocation initiatives. Amortization of intangibles expense remained flat at $17.8 million, compared to the second quarter of 2024. Research and development expense was $17.5 million, compared to $21.0 million in the second quarter of 2024. The decrease in research and development expense was primarily due to lower compensation expense driven by resource optimization and labor allocation initiatives, and timing of planned investments in ENHANZE® related to the development of our new high-yield rHuPH20 manufacturing process. Selling, general and administrative expense was $41.6 million, compared to $35.7 million in the second quarter of 2024. The increase was primarily due to an increase in consulting and professional service fees, including $2.6 million of litigation costs incurred in connection with a patent infringement litigation case, and an increase in compensation expense. Operating income was $202.4 million, compared to $117.2 million in the second quarter of 2024. Net income was $165.2 million, compared to $93.2 million in the second quarter of 2024. EBITDA was $222.9 million, compared to $137.0 million in the second quarter of 2024. Adjusted EBITDA was $225.5 million, compared to $137.0 million in the second quarter of 2024.1 GAAP diluted earnings per share was $1.33, compared to $0.72 in the second quarter of 2024. Non-GAAP diluted earnings per share was $1.54, compared to $0.91 in the second quarter of 2024.1 Cash, cash equivalents and marketable securities were $548.2 million on June 30, 2025, compared to $596.1 million on December 31, 2024. The decrease was primarily a result of share repurchase activities during the year, partially offset by cash generated from operations. Financial Outlook for 2025 The Company is raising its financial guidance for 2025. Note that the guidance reflects tariffs that are currently implemented. For the full year 2025, the Company expects: Total revenue of $1,275 million to $1,355 million, representing growth of 26% to 33% over 2024 total revenue, primarily driven by increases in royalty revenue. Revenue from royalties of $825 million to $860 million, representing growth of 44% to 51% over 2024. Adjusted EBITDA of $865 million to $915 million, representing growth of 37% to 45% over 2024. Non-GAAP diluted earnings per share of $6.00 to $6.40, representing growth of 42% to 51% over 2024. The Company's earnings per share guidance does not consider the impact of potential future share repurchases. Table 1. 2025 Financial Guidance Webcast and Conference Call Halozyme will host its Quarterly Update Conference Call for the second quarter ended June 30, 2025 today, Tuesday, August 5, 2025, at 1:30 p.m. PT/4:30 p.m. ET. The conference call may be accessed live with pre-registration via link: . The call will also be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast and additional documents related to the call, please visit Halozyme.com. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. For more information visit and connect with us on LinkedIn and Twitter. Note Regarding Use of Non-GAAP Financial Measures In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), this press release and the accompanying tables contain certain Non-GAAP financial measures. The Company reports earnings before interest, taxes, depreciation, and amortization ("EBITDA"), adjusted EBITDA, Non-GAAP diluted earnings per share, Non-GAAP diluted shares, and guidance with respect to those measures, in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The Company calculates Non-GAAP diluted earnings per share excluding share-based compensation expense, amortization of debt discounts, intangible asset amortization, one-time items, if any, such as changes in contingent liabilities, inventory adjustments, impairment charges and intellectual property litigation costs, and certain adjustments to income tax expense. The Company calculates Non-GAAP diluted shares excluding the dilutive impact of convertible notes which is used in calculating Non-GAAP diluted earnings. The Company calculates EBITDA excluding interest, taxes, depreciation and amortization. The Company calculates adjusted EBITDA excluding one-time items, if any, such as changes in contingent liabilities, inventory adjustments, impairment charges, transaction costs for business combinations and intellectual property litigation costs. Reconciliations between GAAP and Non-GAAP financial measures are included at the end of this press release. The Company does not provide reconciliations of forward-looking adjusted measures to GAAP due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including adjustments that could be made for changes in share-based compensation expense and the effects of any discrete income tax items. For the same reasons, the Company is unable to address the probable significance of the unavailable information. The Company provides Non-GAAP financial measures that it believes will be achieved; however, it cannot accurately predict all of the components of the adjusted calculations and the GAAP measures may be materially different than the Non-GAAP measures. The Company evaluates other items of income and expense on an individual basis for potential inclusion in the calculation of Non-GAAP financial measures and considers both the quantitative and qualitative aspects of the item, including (i) its size and nature, (ii) whether or not it relates to the Company's ongoing business operations and (iii) whether or not the Company expects it to occur as part of the Company's normal business on a regular basis. Non-GAAP financial measures do not have any standardized meaning and are therefore unlikely to be comparable to similarly titled measures presented by other companies. These Non-GAAP financial measures are not meant to be considered in isolation and should be read in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP, and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that the Company may exclude for purposes of its Non-GAAP financial measures, and the Company may in the future cease to exclude items that it has historically excluded for purposes of its Non-GAAP financial measures. The Company considers these Non-GAAP financial measures to be important because they provide useful measures of the operating performance of the Company, exclusive of factors that do not directly affect what the Company considers to be its core operating performance, as well as unusual events. The Non-GAAP measures also allow investors and analysts to make additional comparisons of the operating activities of the Company's core business over time and with respect to other companies, as well as assessing trends and future expectations. The Company uses Non-GAAP financial information in assessing what it believes is a meaningful and comparable set of financial performance measures to evaluate operating trends, as well as in establishing portions of our performance-based incentive compensation programs. Safe Harbor Statement In addition to historical information, the statements set forth in this press release include forward-looking statements including, without limitation, statements concerning the Company's financial performance (including the Company's expected financial outlook for 2025) and expectations for future growth, profitability, total revenue, royalty revenue, EBITDA, Adjusted EBITDA, and Non-GAAP diluted earnings-per-share, potential share repurchases under its share repurchase program and potential expansion of the Company's platform through acquisitions. Forward-looking statements regarding the Company's ENHANZE® drug delivery technology may include the possible benefits and attributes of ENHANZE® and its potential application to aid in the dispersion and absorption of other injected therapeutic drugs and facilitating more rapid delivery and administration of higher volumes of injectable medications through subcutaneous delivery. Forward-looking statements regarding the Company's business may include potential growth and receipt of royalty and milestone payments driven by our partners' development and commercialization efforts, potential new clinical trial study starts and clinical data, regulatory submissions and product launches, the size, demand and growth prospects of our partners' drug franchises, potential new or expanded collaborations (including potential HVAI and SVAI collaborations) and collaborative targets and regulatory review, and potential approvals of new partnered or proprietary products, and the potential timing of these events. These forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning and involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including unexpected levels of revenues, expenditures and costs, unexpected delays in the execution of the Company's share repurchase program or planned platform expansion through acquisitions, unexpected results or delays in the growth of the Company's business, or in the development, regulatory review or commercialization of the Company's partnered or proprietary products, regulatory approval requirements, uncertainties related to tariff, trade and pharmaceutical pricing policies and tax legislation, unexpected adverse events or patient outcomes and competitive conditions. In addition, there can be no assurance as to developments related to the litigation referred to in this press release, the outcome of the litigation or any remedies that could be awarded in connection with the litigation. These and other factors that may result in differences are discussed in greater detail in the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. Except as required by law, the Company undertakes no duty to update forward-looking statements to reflect events after the date of this release. Contacts: Tram Bui VP, Investor Relations and Corporate Communications 609-333-7668 [email protected] Sydney Charlton Teneo 917-972-8407 [email protected] SOURCE Halozyme Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

点击蓝字关注我们编者按：作为全球肿瘤学领域的顶级盛会，2025年欧洲肿瘤内科学会年会（ESMO 2025）将于10月17日至21日在德国柏林盛大举办。届时，来自世界各地的临床医生、研究人员、患者倡导者、记者和医疗行业专业人士将齐聚一堂，展示开创性的发现、前沿治疗方法，并倡导协作方式，推动肿瘤治疗的未来发展。日前，大会公布了本次入选摘要的标题，其中在血液肿瘤领域共有28项中国研究入选（如遗漏欢迎留言补充），展示了中国在该领域的最新突破与创新成果。以下是入选摘要及相关汇报者的信息，敬请关注。特邀论文报告Proffered Paper session摘要号：1240O英文题目：CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory Large B-cell Lymphoma: a Prospective, Single-arm, Single-center, Phase 2 Clinical Trial中文题目：CD19/CD22双特异性CAR-T细胞治疗复发/难治性大B细胞淋巴瘤：一项前瞻性、单臂、单中心、II期临床试验汇报者：王亮（首都医科大学附属北京同仁医院）摘要号：1241O英文题目：Anti-PD-1-Antibody (Tislelizumab) Combined with Chidamide, Lenalidomide and Etoposide for the treatment of refractory/relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single -Arm, Phase II Trial中文题目：抗PD-1抗体（替雷利珠单抗）联合西达本胺、来那度胺和依托泊苷治疗难治性/复发性鼻型结外自然杀伤/T细胞淋巴瘤：一项前瞻性、多中心、单臂、II期试验的初步结果汇报者：张蕾（郑州大学第一附属医院）小型口头报告Mini Oral session摘要号：1243MO英文题目：Risk Stratification for Diffuse Large B-Cell Lymphoma by Integrating Interim 18F-FDG PET-CT Analysis and the NCCN-IPI: A Multicentre Retrospective Study中文题目：整合中期18F-FDG PET-CT分析和NCCN-IPI对弥漫性大B细胞淋巴瘤进行风险分层：一项多中心回顾性研究汇报者：王杰松（福建省肿瘤医院）摘要号：1245MO英文题目：Combination of Mitoxantrone Hydrochloride Liposome with Chidamide in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma: Updated Results of the Phase II Study中文题目：盐酸米托蒽醌脂质体联合西达本胺治疗复发或难治性外周T细胞淋巴瘤：II期研究更新结果汇报者：李志铭（中山大学肿瘤防治中心）摘要号：1246MO英文题目：Single-Cell Atlas of Circulating Immunity identifies shared specific DLBCL signatures for predicting Response to R-CHOP and Anti-CD19 CAR T Therapies中文题目：单细胞循环免疫图谱揭示了可预测对R-CHOP和抗CD19 CAR-T疗法应答的共同特异性DLBCL特征汇报者：张思聪（天津医科大学肿瘤医院）摘要号：1247MO英文题目：Molecular Landscape of Distinct Follicular Lymphoma Histologic Grades: Insights from Genomic and Transcriptome Analyses中文题目：不同滤泡性淋巴瘤组织学分级的分子图谱：来自基因组和转录组分析的见解汇报者：孙聪（天津医科大学肿瘤医院）摘要号：1248MO英文题目：Changes in Peripheral Blood Leukemia Stem Cells, Immune Cell Subsets, Cytokines, and Cellular Differentiation Status Before and After Venetoclax-Containing Regimen Treatment for Acute Myeloid Leukemia中文题目：急性髓系白血病含维奈克拉方案治疗前后外周血白血病干细胞、免疫细胞亚群、细胞因子及细胞分化状态的变化汇报者：Xinyu Sun（中国合肥）壁报与电子壁报Posters and ePosters摘要号：1251P 英文题目：DLBCL-associated PIM1 mutation drives ANXA2 relocation on the membrane and promotes lymphomagenesis through PI3K/AKT/mTOR pathway中文题目：DLBCL相关的PIM1突变驱动ANXA2移位至膜上并通过PI3K/AKT/mTOR通路促进淋巴瘤发生汇报者：Yaxiao Lu (中国天津)摘要号：1254P英文题目：Clinical features, management, and prognostic factors of patients with primary pulmonary mucosa-associated lymphoid tissue lymphoma中文题目：原发性肺黏膜相关淋巴组织淋巴瘤患者的临床特征、管理及预后因素汇报者：Yizhen Liu (中国上海)摘要号：1256P英文题目：Integrating Transcriptomic Profiling and Machine Learning: A Clinically Actionable Prognostic Model for Infant Acute Myeloid Leukemia中文题目：整合转录组学分析与机器学习：婴儿急性髓性白血病的临床可操作预后模型汇报者：Yu Tao (中国重庆)摘要号：1257P英文题目：Phase I Randomized, Double-Blind, Parallel Study to Compare Pharmacokinetics, Safety, and Immunogenicity of QL2109 with DARZALEX FASPRO? in Healthy Male Participants中文题目：比较QL2109与DARZALEX FASPRO在健康男性参与者中的药代动力学、安全性和免疫原性的I期随机、双盲、平行研究汇报者：Xingjiang Hu (中国杭州)摘要号：1262P英文题目：A Deep Learning-Based Digital Pathology Model for Predicting MYC, BCL2, and BCL6 Rearrangements in DLBCL中文题目：基于深度学习的数字病理模型用于预测DLBCL中MYC、BCL2和BCL6的重排汇报者：Xujie Sun (中国北京)摘要号：1264P英文题目：Orelabrutinib plus Rituximab-based chemoimmunotherapy regimens in relapsed or refractory marginal zone lymphoma: a multicentric phase II trial中文题目：奥布替尼联合利妥昔单抗治疗复发或难治性边缘区淋巴瘤的化学免疫治疗方案：一项多中心II期临床试验汇报者：Shaohua Wu (中国太原)摘要号：1265P英文题目：Orelabrutinib with Anti-CD20 monoclonal antibodies is highly effective and well tolerated as first-line therapy for marginal zone B cell lymphoma中文题目：奥布替尼联合抗CD20单克隆抗体一线治疗边缘区B细胞淋巴瘤的疗效显著且耐受性良好汇报者：Na Yao (中国北京)摘要号：1266P英文题目：Proteolysis-targeting chimera (PROTAC) targeting BTK degradation for cancer therapy in mantle cell lymphoma中文题目：靶向BTK降解的蛋白降解靶向嵌合体（PROTAC）在套细胞淋巴瘤癌症治疗中的应用汇报者：Xiaohui Wang (中国天津)摘要号：1269P英文题目：Loss of MGAT3 promotes airway fibrosis in patients with bronchiolitis obliterans by enhancing TGF-β signaling中文题目：MGAT3缺失通过增强TGF-β信号通路促进支气管炎性小气道纤维化汇报者：Wei Ge (中国苏州)摘要号：1270P英文题目：Safety and efficacy of a pre-phase with dexamethasone followed by fractioned R-CHOP in diffuse large B cell lymphoma patients with gastrointestinal involvement at diagnosis中文题目：地塞米松预处理联合R-CHOP分次治疗对确诊时有胃肠道损害的弥漫大B细胞淋巴瘤患者的安全性和有效性汇报者：Ke Cui (中国上海)摘要号：1274P英文题目：A transcriptomic model accurately predicting hematopoietic stem cell transplantation survival in pediatric acute myeloid leukemia中文题目：准确预测儿童急性髓系白血病造血干细胞移植存活率的转录组模型汇报者：Yance Feng (中国重庆)摘要号：1275P英文题目：Efficacy and Safety of Low-Dose TBI Combined MAC Regimen for HSCT in High-Risk AML Patients with Active Disease中文题目：低剂量TBI联合MAC方案对活动期高危AML患者造血干细胞移植的疗效及安全性汇报者：Pengfei Shi (中国杭州)摘要号：1276P 英文题目：Efficacy and Safety of Tafasitamab Combined with Lenalidomide in Patients with Diffuse Large B-Cell Lymphoma: A Matched-Adjusted Indirect Comparison Based on a Global Trial中文题目：Tafasitamab联合来那度胺治疗弥漫大B细胞淋巴瘤的疗效和安全性：基于全球试验的匹配调整间接比较汇报者：Wenyu Li (中国广州)摘要号：1279P英文题目：Risk Stratification and Therapeutic Suggestions for High-risk RUNX1::RUNX1T1-positive pAML patients中文题目：高危 RUNX1::RUNX1T1 阳性pAML患者的风险分层和治疗建议汇报者：Yang Xun (中国佛山)摘要号：1281P英文题目：Targeting miR-20a/RUNX1 exerts the dual functions of blocking CD8+ T cell exhaustion and anti-leukemia effect in acute myeloid leukemia中文题目：靶向 miR-20a/RUNX1在急性髓系白血病中发挥阻断CD8+ T细胞耗竭和抗白血病作用的双重作用汇报者：Yangqiu Li (中国广州)摘要号：1285P英文题目：HIF-2α expression predicts inferior survival and can broaden the poor clinical outcome of patients with Foxp3- and NF-κB+ in DLBCL中文题目：HIF-2α表达预示较差的生存期，并可加剧伴有Foxp3和NF-κB+的DLBCL患者的临床不良结局汇报者：Yaoyao Jing (中国天津)摘要号：1291eP英文题目：Pola-R-CHP Regimen as First-Line Treatment for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma (DLBCL) Patients中文题目：Pola-R-CHP方案作为新诊断高危弥漫大B细胞淋巴瘤 (DLBCL)患者的一线治疗汇报者：Jinping Pi (中国北京)摘要号：1294eP英文题目：Efficacy of Orelabrutinib Combined with R-CHOP(-like) Regimen in Previously Untreated Double-expression (DE) Diffuse Large B-Cell Lymphoma (DLBCL): A Single-Center Real-World Analysis中文题目：奥布替尼联合R-CHOP(类)方案治疗既往未治疗的双表达(DE)弥漫大B细胞淋巴瘤(DLBCL)的疗效：单中心真实世界分析汇报者：Min Bai (中国太原)摘要号：1298eP英文题目：PD-1/CD20 Dual-Target Therapy in Unfit Diffuse Large B-Cell Lymphoma: A Real-World Pilot Study中文题目：PD-1/CD20双靶点疗法治疗Unfit弥漫大B细胞淋巴瘤：一项真实世界先导研究汇报者：Shaozhen Chen (中国福州)摘要号：1299eP 英文题目：ADGRE2: a tumor-restricted surface antigen for immunotherapy in acute myeloid leukemia中文题目：ADGRE2：急性髓性白血病免疫治疗的肿瘤特异性表面抗原汇报者：Ruotong Chen(中国合肥)摘要号：1300eP英文题目：Synergistic Effect of Vincristine and Cytarabine via Targeting the ALDOC-JAK/STAT Axis for NRASmut Acute Myeloid Leukemia中文题目：长春新碱与阿糖胞苷通过靶向ALDOC-JAK/STAT轴对NRASmut急性髓系白血病的协同效应汇报者：Haotian Yan(中国合肥)（来源：《肿瘤瞭望–血液时讯》编辑部）声 明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。